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Abstract
Background: Diminished activity of the enzyme AMP-activated protein kinase (AMPK) is associated with
impaired insulin signaling.
Results: Protein Kinase (PK)C/D1 activation inhibits AMPK2 via Ser491 phosphorylation; PKD1 inhibition
prevents this in skeletal muscle cells.
Conclusion: PKD1 is a novel upstream AMPK-kinase that phosphorylates AMPK on Ser491 and regulates
insulin signaling.
Significance: PKD1 inhibition may be a novel strategy for improving insulin sensitivity.
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Background:Diminished activity of the enzyme AMP-activated protein kinase (AMPK) is associated with impaired insulin
signaling.
Results: Protein Kinase (PK)C/D1 activation inhibits AMPK2 via Ser491 phosphorylation; PKD1 inhibition prevents this in
skeletal muscle cells.
Conclusion: PKD1 is a novel upstream AMPK-kinase that phosphorylates AMPK on Ser491 and regulates insulin signaling.
Significance: PKD1 inhibition may be a novel strategy for improving insulin sensitivity.
AMP-activated protein kinase (AMPK) is an energy-sensing
enzyme whose activity is inhibited in settings of insulin resis-
tance. Exposure to a high glucose concentration has recently
been shown to increase phosphorylation of AMPK at Ser485/491
of its 1/2 subunit; however, the mechanism by which it does
so is not known. Diacylglycerol (DAG), which is also increased in
muscle exposed to high glucose, activates a number of signaling
molecules includingproteinkinase (PK)CandPKD1.Wesought to
determine whether PKC or PKD1 is involved in inhibition of
AMPK by causing Ser485/491 phosphorylation in skeletal muscle
cells. C2C12 myotubes were treated with the PKC/D1 activator
phorbol 12-myristate 13-acetate (PMA), which acts as a DAG
mimetic. This caused dose- and time-dependent increases in
AMPK Ser485/491 phosphorylation, which was associated with a
60% decrease in AMPK2 activity. Expression of a phosphode-
fective AMPK2 mutant (S491A) prevented the PMA-induced
reduction in AMPK activity. Serine phosphorylation and inhibi-
tion of AMPK activity were partially prevented by the broad PKC
inhibitor Go¨6983 and fully prevented by the specific PKD1 inhibi-
tor CRT0066101. Genetic knockdown of PKD1 also prevented
Ser485/491 phosphorylation of AMPK. Inhibition of previously
identified kinases that phosphorylate AMPK at this site (Akt, S6K,
andERK)didnotprevent theseevents.PMAtreatmentalso caused
impairments in insulin-signaling through Akt, which were pre-
ventedbyPKD1 inhibition. Finally, recombinantPKD1phosphor-
ylated AMPK2 at Ser491 in cell-free conditions. These results
identify PKD1 as a novel upstream kinase of AMPK2 Ser491 that
plays a negative role in insulin signaling inmuscle cells.
Skeletalmuscle is responsible for80%of insulin-stimulated
glucose uptake in healthy humans (1). Thus, tight regulation of
insulin signaling and glucose uptake in muscle cells is essential
to maintaining normal blood glucose levels and overall meta-
bolic health. This process can become dysregulated in patho-
logical settings of insulin resistance, such as type 2 diabetes
(T2D),2 which currently affects over 300 million people world-
wide (2). At a cellular level, prolonged exposure to excess nutri-
ents, such as glucose, leucine, and free fatty acids (FFA), can
impair the signaling processes that normally regulate glucose
uptake. Though these pathways have been studied in detail, a
better understanding of the pathological changes that lead to
dysfunctional insulin signaling is essential for improving ther-
apeutic strategies.
AMP-activated protein kinase (AMPK) is an energy sensing
enzyme that is regarded as amaster regulator of cellularmetab-
olism (3). This serine/threonine kinase is activated when cellu-
lar energy levels are low (high AMP:ATP ratio) and its activa-
tion signals for the cell to increase catabolic (energy generating)
processes, such as glucose uptake and fatty acid oxidation, and
to inhibit anabolic (energy consuming) processes, such as pro-
tein and triglyceride synthesis. AMPK is activated by both its
phosphorylation on Thr172 and allosteric modification of its
catalytic-subunit. ActivatedAMPK, in turn,mediates someof
the beneficialmetabolic effects of exercise andpharmacological
activators, such as biguanides, and thiazolidinediones, which
improve insulin sensitivity. Recent studies suggest that an
inhibitory phosphorylation site at Ser485/491 of AMPK 1/2
subunits plays an important role in diminishing its enzyme
activity (4–7). We recently found that incubation of rat exten-
sor digitorum longus (EDL)muscle with elevated glucose levels
(25 versus 5.5 mM) for 1 or 2 h both increased the phosphoryla-
tion of AMPK at Ser485/491 and diminished its phosphorylation
at Thr172, both of which decreased its enzyme activity, as mea-
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sured by the SAMS peptide assay (8). Similarly, it has been
reported that when MIN6 pancreatic beta cells are switched
from low glucose (3 mM) culture medium to high glucose (25
mM) for either 1 h or overnight, phosphorylation of AMPK1 at
Ser485 is increased, and phosphorylation at Thr172 is dimin-
ished (9).
Several upstreamkinaseshavebeen identified that phosphor-
ylate AMPK at Ser485/491 and inhibit its activity in various tis-
sues. For example, in heart, skeletal muscle, and liver, insulin
and IGF-1 stimulate AMPKphosphorylation at this site by acti-
vating Akt (4, 7, 10, 11). Also, in the hypothalamus, Dagon et al.
(4, 5) showed that p70S6K phosphorylates AMPK2 Ser491 to
inhibit AMPK activity and decrease food intake. Others have
shown that in murine macrophage-like RAW 264.7 cells, IKK
phosphorylates AMPK at Ser485 in response to LPS treatment
(12), while ERK1/2 can inhibit AMPK by this mechanism in
mature dendritic cells in response to CCR7 signaling (13).
Finally, protein kinase A (PKA) has been reported to phosphor-
ylate this site in INS-1 cells in response to forskolin or GIP
stimulation (14) and in humandiploid fibroblasts in response to
lysophosphatidic acid (15). Inhibition of AMPK through this
mechanism by multiple kinases suggests a biological need to
maintain tight control over AMPK enzyme activity. Whether
still other kinases also phosphorylate AMPK at Ser485/491 to
modulate its activity and biological functions remain to be
determined.
Protein kinaseC (PKC) is a family of serine/threonine kinases
that can be activated by diacylglycerol (DAG), a phospholipid,
and Ca2 (depending on the isoform). Several of the 10 known
PKC isoforms have long been implicated in the development of
insulin resistance, but beyond inhibitory serine phosphoryla-
tion of IRS-1 (16), themechanisms bywhich they do so have not
been fully clarified. Protein kinase D1 (PKD1) (the mouse
ortholog of human PKC) is a related kinase that can be acti-
vated either directly by DAG or due to phosphorylation by
novel PKC isoforms (17). When activated, PKD1 undergoes
transphosphorylation by novel PKCs at Ser744/748 of its activa-
tion loop and autophosphorylation at Ser916 at its C terminus.
Thismore recently discovered enzymewas initially classified as
an atypical PKC isoform, but was later determined to be more
similar structurally to the calcium/calmodulin-dependent pro-
tein kinase (CaMK) group of serine/threonine kinases with
unique substrate specificity (17, 18). Pathological overactiva-
tion of PKD1 has been linked to the invasiveness of certain
cancers (19) and to cardiac hypertrophy (20, 21), the latter of
which is often present in patients with T2D. Whether altera-
tions in PKD1 expression or activity affect AMPK activation is
not yet known. What is clear is that the DAGmimetic phorbol
12-myristate 13-acetate (PMA), which activates PKC and
PKD1, as well as many other signaling molecules, decreases
AMPK activity in cardiac myocytes (22), although the mecha-
nism by which it does so is unknown.
In the present study, we sought to determinewhether PKCor
PKD1 is involved in the inhibition of AMPK by phosphoryla-
tion at Ser485/491 in skeletal muscle cells. We used the phorbol
ester PMA to determine the effects of broad PKC/PKD1 acti-
vation on AMPK phosphorylation and activity. By the use of
nonspecific and specific PKC and PKD1 inhibition, we show for
the first time that PKD1 phosphorylates AMPK at Ser485/491,
thus diminishing AMPK activity.
Experimental Procedures
Materials—C2C12 cells were purchased from ATCC
(Manassas, VA). DMEM, Penicillin-Streptomycin (P/S), fetal
bovine serum (FBS), and horse serum (HS) were from Invitro-
gen (Grand Island,NY). D-()-Glucose solution, 45%, and insu-
lin were obtained from Sigma-Aldrich. Primary antibodies for
acetyl-CoA carboxylase (ACC), AMPK, phospho-AMPK
(Thr172), phospho-AMPK1/2 (Ser485/491), phospho-PKD1
(Ser916), phospho-PKD1 (Ser744/748), PKD1, phospho-PKC
(pan) (II Ser660), phospho-PKC/ (Ser643/676), phospho-(Ser)
PKC Substrate, phosphor-(Ser/Thr) PKD substrate, phospho-
mTOR (Ser2448),mTOR, phospho-p70S6K (Thr389), phosphor-
ERK (Thr202/Tyr204), phospho-Akt (Ser473), and Akt antibod-
ies, as well as secondary horseradish peroxidase (HRP)-linked
antibodies were purchased from Cell Signaling Technology
(Danvers, MA). Phospho-ACC (Ser79) antibody was from
Upstate/Millipore (Temecula, CA). Anti--actin and anti-
FLAGwere purchased from Sigma-Aldrich. PRKD1 siRNA and
corresponding negative control scrambled siRNA were pur-
chased from Thermo Fisher Scientific (Waltham, MA).
AMPK1 and 2 antibodies used for immunoprecipitation
were purchased from Santa Cruz Biotechnology, Inc. SAMS
peptide was purchased from Abcam (Cambridge, MA) and
[-32P]ATP was from Perkin-Elmer (Boston, MA).
Cell Culture—C2C12myoblastswere cultured in normal glu-
cose (5.5 mM) DMEM supplemented with 10% fetal bovine
serum (FBS), 1% glutamine, and 1% penicillin/streptomycin
(P/S). Mediumwas replaced every 24–48 h, and cells were pas-
saged upon reaching 80–90% confluence. At 80–90% conflu-
ence they were differentiated into myotubes in DMEM supple-
mentedwith 2% horse serum and 1%P/S. Glucose and FBS-free
DMEM, supplemented with 1% P/S and glucose at a final con-
centration of 5.5mM,was used for all experimental incubations.
Transfection Studies—Cells were transfected with Lipo-
fectamine 3000 (for FLAG-WTAMPK2/FLAG-S491AAMPK2
studies) or Lipofectamine RNAimax (for siRNA studies)
according to themanufacturer’s instructions. C2C12 cells were
transfected on day 3 of differentiation, and experiments were
performed on day 5 of differentiation.
Cell Lysate Preparation—Cells were washed once on ice with
Dulbecco’s PBS, lysed in buffer containing 20mMTris-HCl, pH
7.5, 150 mMNaCl, 1 mMNa2EDTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1
g/ml leupeptin, 1 phosphatase inhibitor mixture 3 (Sigma),
and 1x protease inhibitor mixture containing 0.5 mM EDTA
(Thermo Fisher Scientific), and removed fromwells using a cell
scraperwith a polyethylene copolymer blade (Fisher Scientific).
Cell debris was removed by centrifugation at 13,200 g for 10
min at 4 °C, and the supernatant was removed and stored at
80 °C until analysis. Protein concentration was assessed by
the bicinchoninic acid method (BCA; Pierce Biotechnology,
Inc., Rockford, IL).
SDS-PAGE Western Blot Analysis—Protein expression and
phosphorylationwere determined in 15–30g of protein lysate
using SDS-PAGE gel electrophoresis and immunoblotting. Fol-
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lowing transfer onto a polyvinylidene difluoride membrane,
membranes were blocked in Tris-buffered saline (pH 7.5) con-
taining 0.05% Tween-20 (v/v; TBST) and 5% nonfat dry milk
(w/v) for 1 h at room temperature, followed by incubation in
primary antibodies (1:1,000) at 4 °C overnight. After washing,
membraneswere incubated in a secondary antibody conjugated
to horseradish peroxidase at a 1:5,000 dilution for 1 h at room
temperature. Bands were visualized using enhanced chemilu-
minescence solution (ECL; Pierce Biotechnology, Inc., Rock-
ford, IL), and densitometry was performed with Scion Image
software.
AMPKActivity Assay—AMPK activity was assessed as previ-
ously described (23, 24). Briefly, AMPK 1 or 2 was immuno-
precipitated from 500g of protein from cell lysates by incuba-
tion at 4 °C overnight on a roller mixer using AMPK 1 or
2-specific antibodies (1:80) and protein A/G-agarose beads
(1:10; Santa Cruz Biotechnology, Inc). Following several
washes, activity was measured in the presence of 200 M AMP
and 80 M [-32P]ATP (2 Ci) using 200 M SAMS peptide
(Abcam) as a substrate. Label incorporation into the SAMS
peptide was quantified using a LabLogic (Brandon, FL) scintil-
lation counter.
Cell-free in Vitro Phosphorylation Assay—Recombinant pro-
teins were purchased from EMD Millipore (Billerica, MA)
(AMPK) and Enzo Life Sciences (Farmington, NY) (PKD1 and
Akt). Recombinant 2AMPK/1/1 complex was incubated
with recombinant Akt or PKD1 in 50 mM Na-HEPES, 5 mM
MgCl2, 500 M ATP, 1 mM DTT for 30 min at 30 °C.
Statistical Analysis—Results are reported as means S.E. of
the mean (S.E.). Statistical significance was determined by two-
tailed unpaired Student’s t tests or ANOVA with Tukey’s post-
hoc test. A level of p  0.05 was considered statistically
significant.
Results
The PKC Activator PMA Dose- and Time-dependently Stim-
ulates AMPK Ser485/491 Phosphorylation in C2C12Myotubes—
Treatment with the PKC activator phorbol 12-myristate 13-ac-
etate (PMA) has previously been shown to decrease AMPK
activity in cardiac myocytes, as measured by the SAMS peptide
assay (22).We sought to determinewhether PMAhad the same
effect in C2C12 myotubes, and if so, whether it is mediated by
an inhibitory phosphorylation on AMPK 1/2 subunit at
Ser485/491. All doses of PMA (10–100 nM) significantly
increased serine phosphorylation of AMPK (Fig. 1, A and B), as
did PMA treatment for 30 min to 3 h (50 nM) (Fig. 1, C and D).
Increases in overall PKC activity, as measured by serine phos-
phorylation of PKC substrates (data not shown), mirrored the
increases in phosphorylation of AMPK Ser485/491. Phosphoryl-
ation of PKD at Ser916 and Ser744/748 of its activation loop were
also significantly increased by incubation with PMA at doses of
25 nM or higher for 30min to 3 h (Fig. 1,A–D). Since phosphor-
ylation of these two sites changed similarly in response to all
treatments, only the data for Ser916 phosphorylation is shown
for subsequent experiments. Notably, no significant changes in
phosphorylation of AMPKThr172 (Fig. 1,A andC) or its down-
stream substrate ACC Ser79 (data not shown) were observed.
Phosphorylation of conventional PKC isoforms, as measured
by p-PKC (pan) (II Ser660), was increased in a dose-response
manner; however, activation of the atypical PKC was not
increased by PMA treatment (data not shown).
The Non-selective PKC Inhibitor Go¨6983 Prevents PMA-in-
duced Phosphorylation of AMPK Ser485/491in the Myotubes—
To determine whether the increase in phosphorylation of
AMPK at Ser485/491 was attributable to PKC activation, we used
the non-selective PKC inhibitor Go¨6983. Treatment of C2C12
myotubes with Go¨6983 (5 M) for 1 h prior to PMA treatment
(50 nM, 30 min) significantly attenuated phosphorylation of
AMPKat Ser485/491 (Fig. 2,A andB). Phosphorylation of AMPK
Thr172 (Fig. 2A) was not affected by PMA treatment, but it was
increasedby the inhibitor.PKCactivity, assessedbyserinephos-
phorylation of PKC substrates, was decreased by the inhibitor
(Fig. 2A), as was phosphorylation of conventional PKC iso-
forms, when evaluated by phospho-PKC  pan, and PKD at
Ser916 (Fig. 2, A and B), but not PKC / (data not shown).
The Selective PKD1 Inhibitor CRT0066101 Prevents PMA-
inducedPhosphorylation of AMPKSer485/491—Since phosphor-
ylation of the activation loop of PKD at Ser744/748 and at Ser916
(Fig. 2,A andB) correspondedwith changes in phosphorylation
of AMPK at Ser485/491, we investigated whether specific inhibi-
tion of PKD could attenuate PMA-induced serine phosphory-
lation of AMPK. Pre-treatment for 1h with the specific PKD
inhibitor CRT0066101 (10 M) prevented phosphorylation of
AMPK Ser485/491 in C2C12 myotubes (Fig. 2, C and D). Phos-
phorylation of AMPK at Thr172 was unchanged by treatment
with this inhibitor (Fig. 2C). As expected, PMA effects on PKD
Ser916 phosphorylation were ablated by CRT0066101 treat-
ment, and probing with a phospho-(Ser/Thr) PKD substrate
antibody revealed an overall increase in number of bands and
band intensity with PMA treatment, which was prevented by
pretreatment with CRT0066101 (Fig. 2C). Bands detected by
this antibody at 110 kDa and 62 kDamay represent PKD (which
is autophosphorylated at Ser916) and AMPK, respectively.
PMATreatment Inhibits AMPKActivity, which IsAttenuated
by Pretreatment with Go¨6983 or CRT0066101—Recent studies
have shown that phosphorylation of AMPK Ser485/491 can
inhibit its activity, even in the absence of diminished Thr172
phosphorylation, which is often used as a surrogate readout for
enzyme activity (4, 5). We sought to determine whether the
changes in phosphorylation of AMPK Ser485/491 caused by
PMA and the PKC/D inhibitors Go¨6983 and CRT0066101 cor-
responded to changes in AMPK activity. Using the SAMS pep-
tide assay described in themethods section, we found that PMA
treatment significantly decreased AMPK2 activity in C2C12
myotubes (Fig. 3,A andC). Furthermore, pretreatmentwith the
non-selective PKC inhibitor Go¨6983 significantly attenuated
the reduction in enzyme activity (Fig. 3A), while the specific
PKD inhibitor CRT0066101 completely prevented the PMA-
induced decrease inAMPKactivity (Fig. 3C). Despite the lack of
changes in phosphorylation of AMPK Thr172 or ACC Ser79, we
found a significant inverse correlation betweenAMPK2 activ-
ity and phosphorylation at Ser485/491 (Fig. 3, B and D).
Phosphorylation of AMPK2 on Ser491 Is Necessary for PMA-
induced Inhibition of AMPK Activity—To determine if serine
phosphorylation is required for the PMA-induced reduction
in AMPK activity, C2C12 cells were transfected with WT
PKD1 Inhibits AMPK2 Activity via Phosphorylation on Ser491
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AMPK2 or phosphodefective S491AAMPK2. As expected,
phosphorylation of AMPK at Ser491 under both basal and
PMA-treated conditions was prevented in the S491A
AMPK2-expressing cells (Fig. 3E). While PMA significantly
decreased AMPK2 activity, asmeasured by the SAMS peptide
assay, in cells transfected withWTAMPK2, no effect of PMA
treatment was observed in the S491A AMPK2-expressing
cells. These data suggest that Ser491 phosphorylation of
AMPK2 is required for the PMA-induced inhibition ofAMPK
activity.
Knockdown of PKD1 Prevents PMA-induced Phosphorylation
of AMPK Ser485/491—To confirm the results obtained using
pharmacological inhibitors which suggested that PKD1 is in-
volved in PMA-induced AMPK Ser485/491 phosphorylation (Fig.
2), we used siRNA to reduce PKD1 mRNA, and hence protein,
levels. As expected, transfection of C2C12 cells with PKD1 (gene
name PRKD1) caused a reduction in phospho-PKD1 (Fig. 4, A
and B). Consistent with data shown in Fig. 2, PKD1 knockdown
prevented thePMA-induced increase inAMPKSer485/491 phos-
phorylation. These data offer further evidence that PKD1 is
responsible for PMA-induced inhibition of AMPKby Ser485/491
phosphorylation.
Inhibition of Akt, P70S6K, or ERK Does Not Prevent PMA-
induced Phosphorylation of AMPK Ser485/491—As previously
mentioned, the kinases Akt, P70S6K, and ERK1/2 have been
shown to phosphorylate AMPK at Ser485/491 in response to var-
ious stimuli in other cell types. To rule out involvement of these
kinases in PMA-induced phosphorylation of AMPK Ser485/491,
FIGURE 1. PMA treatment time- and dose-dependently stimulates phosphorylation of AMPK at Ser485/491 in C2C12myotubes.Myotubes were treated
with10–100nMPMA for 30min (A,B) or 50nMPMA for 5–180min (C,D). Cellswere lysedandprotein expressionandphosphorylationwere analyzedbyWestern
blot. Representative Western blots (A, C) and their densitometric analyses (B, D) are shown. Results are means S.E. (n 3–6 per treatment). All experiments
were performed in triplicate. *, p 0.05 compared with control.
PKD1 Inhibits AMPK2 Activity via Phosphorylation on Ser491
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we used inhibitors of each of these kinases. Pretreatment of
C2C12 myotubes with the PI3K/Akt inhibitor wortmannin
(100 nM) did not affect PMA-stimulated serine phosphoryla-
tion of AMPK (Fig. 5A). As expected, PMA treatment did not
increase Akt phosphorylation, but p-Akt Ser473 phosphoryla-
tion was diminished by wortmannin treatment. Next, we used
the mTOR inhibitor rapamycin to test whether P70S6K was
involved. Although P70S6K Thr389 phoshphorylation was
increased by PMA treatment, rapamycin (100 nM) treatment
did not did not affect PMA-induced phosphorylation of AMPK
Ser485/491 (Fig. 5B). Similarly, pretreatmentwith the ERK inhib-
itor U0126 (5 M) had no effect on AMPK serine phosphoryla-
FIGURE 2. PKD inhibition prevents PMA-induced phosphorylation of AMPK Ser485/491 in C2C12myotubes.Myotubes were treated with the nonspecific
PKC inhibitor Go¨6983 (5 M) (A, B) or the specific PKD inhibitor CRT0066101 (10 M) (C, D) for 1 h prior to PMA treatment (50 nM, 30 min). Cells were lysed and
protein expression and phosphorylationwere analyzed byWestern blot. RepresentativeWestern blots (A, C) and their densitometric analyses (B,D) are shown.
Results are means S.E. (n 3–6 per treatment). All experiments were performed in triplicate. *, p 0.05 compared with control; †, p 0.05 compared with
PMA treatment.
FIGURE 3. PMA treatment diminishes AMPK activity in C2C12myotubes, while PKC and PKD inhibition or expression of S491A AMPK2 prevent this
decrease.C2C12myotubeswere treatedwith the nonspecific PKC inhibitor Go¨6983 (5M) (A) or the specific PKD inhibitor CRT0066101 (10M) (C) for 1 h prior
to PMA treatment (50 nM, 30 min). AMPK2 activity was measured by the SAMS peptide assay. B and D show the correlation between AMPK2 activity and
Ser485/491 phosphorylation. E, C2C12 cells were transfected with FLAG-tagged WT AMPK2 or S491A AMPK2. 48 h later, cells were treated with PMA (50 nM,
30min) and then lysed and immunoprecipitated using an anti-FLAG antibody. Protein phosphorylation and expressionwere analyzed byWestern blot. AMPK
activitywasmeasuredusing theSAMSpeptide assay. Results aremeansS.E. (n3–6per treatment). *,p0.05 comparedwith control; †,p0.05 compared
with PMA treatment.
PKD1 Inhibits AMPK2 Activity via Phosphorylation on Ser491
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tion (Fig. 5C), despite inhibiting ERK phosphorylation, which
can occur downstream of PKD.
PMA Treatment Inhibits Insulin Signaling through Akt,
which Is Attenuated by Pretreatment with Go¨6983 or
CRT0066101, or by PKD1 Knockdown—To test whether the
PMA-induced changes were associated with impaired insulin
signaling, we measured insulin-stimulated Akt phosphoryla-
tion. PMA treatment (50 nM) for 30 min diminished insulin-
stimulated Akt Ser473 phosphorylation (Fig. 6, A and B). Pre-
treatment with Go¨6983 or CRT0066101 restored insulin
signaling through Akt. Since both insulin and PMA indepen-
dently stimulate AMPK Ser485/491 phosphorylation through
Akt and PKD, respectively, all combinations of insulin and
PMAwith and without inhibitors significantly increased serine
phosphorylation of AMPK (Fig. 6, A and B). Similarly, siRNA
mediated knockdown of PKD1 also restored insulin signaling
through Akt (Fig. 6, C and D). PKD1 knockdown, however, did
not prevent PMA-induced serine phosphorylation of IRS-1,
which is known to impair insulin signaling. Thus, this suggests
that PKD1 activation impairs insulin signaling through a novel
mechanism, independent of IRS-1 phosphorylation.
Expression of S491A AMPK2 Prevents PMA-induced
Impairments in Insulin-signaling through Akt—To evaluate
whether AMPK was involved in the diminished insulin-stimu-
lated Akt phosphorylation following PMA treatment, we trans-
fected cells with phosphodefective S491A AMPK2. While
PMA treatment significantly reduced insulin-stimulated Akt
Ser473 phosphorylation in cells expressing WT AMPK2, this
effect was not seen in cells expressing the phosphodefective
AMPK2 (Fig. 7). These data suggest that AMPK Ser491 is
required for PMA to impair insulin signaling through Akt.
Recombinant PKD1 Phosphorylates AMPK2 at Ser491 in
Cell-freeConditions—Todetermine if PKD1directly phosphor-
ylates AMPK or if an intermediate signaling molecule is neces-
sary, we tested whether recombinant PKD1 phosphorylates
AMPK in a cell-free system. Compared with AMPK2 alone,
co-incubation of recombinant PKD1 with AMPK2 caused
phosphorylation of AMPK2 at Ser491 (Fig. 8A). Incubation of
Akt, used as a positive control, with AMPK also caused an obvi-
ous increase in Ser491 phosphorylation. These data suggest that
PKD1 phosphorylates AMPK directly. To evaluate whether
AMPK2 Ser491 is a good substrate for PKD1, we lined up the
PKD1 substrate consensus sequence with the sequence of resi-
dues preceding Ser491 on AMPK2. Although AMPK2 has a
proline rather than PKD1 preferred leucine at the5 position,
the arginine at the 3 position does line up (Fig. 8B). This is
similar to Akt, which prefers arginine at both the 5 and 3
positions.
Discussion
A better understanding of how AMPK is regulated at a
molecular level is important for improving drug-targeting
strategies for T2D. Phosphorylation of AMPK at Thr172 of the
activation loop is generally held to be essential for the activation
ofAMPKand is often used as a readout for its activity.However,
our data add to a growing number of studies showing that phos-
phorylation of AMPK at Ser485/491 can inhibit AMPK activity,
even in the absence of changes in p-AMPK Thr172 (4, 5). These
FIGURE 4. PKD1 knockdown prevents PMA-induced phosphorylation of AMPK Ser485/491 in C2C12 myotubes. C2C12 myotubes were transfected with
scrambled or PKD1 siRNA. 48 h later, they were treatedwith PMA (50 nM, 30min). Cells were lysed, and protein expression and phosphorylationwere analyzed
by Western blot. Representative Western blots (A) and their densitometric analyses (B) are shown. Results are means  S.E. (n  3–6 per treatment). All
experiments were performed in triplicate. *, p 0.05 compared with control; †, p 0.05 compared with PMA treatment.
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data suggest that phosphorylation of AMPK at Ser485/491 can
inhibit AMPK activity independent of changes in p-AMPK
Thr172 and that inhibition of p-AMPK Thr172 is not required
for Ser485/491 phosphorylation to induce inhibition of AMPK
activity. We also show, for the first time, that PKD1 activation
can stimulate phosphorylation of AMPK Ser485/491 in skeletal
muscle cells, resulting in impaired insulin signaling. In addition
to identifying a novel kinase that can inhibit AMPK via
Ser485/491 phosphorylation, these studies present a possible
mechanism by which AMPK may be inhibited by excess nutri-
ents, since DAG (which activates PKD1) is known to be
increased by high glucose and lipids.
In 2012, Tsuchiya et al. (22) demonstrated that 60 min of
PMA treatment (1 M) inhibits AMPK activity by 33% in
cardiac myocytes, as measured by the SAMS peptide assay.
They found that this inhibition could be prevented by the non-
specific PKC inhibitor bisindoylmaleimide I (BIM I) and by the
ERK inhibitor U0126, which led them to conclude that PMA
inhibits AMPK by a mechanism involving the PKC and ERK
pathways. Therewas no apparent change in energy state (AMP/
ATP ratio) accompanying this decrease in AMPK activity. To
our knowledge, thiswas the first report of PMA treatment caus-
ing inhibition of AMPK; however, AMPK phosphorylation at
Thr172 or Ser485/491 was not measured. In concert with these
results, we found that PMA treatment significantly diminished
AMPK activity in C2C12 myotubes (Fig. 3A, 3C). However, we
found that a dose of only 50 nM for 30min resulted in a 50–60%
decrease in AMPK activity, nearly twice as much as was seen in
FIGURE 5. Inhibition of Akt, S6K, or ERK does not prevent PMA-induced phosphorylation of AMPK Ser485/491.Myotubes were treated with the PI3K/Akt
inhibitor wortmannin (100 nM) (A), themTOR/P70S6K inhibitor rapamycin (100 nM) (B), or the ERK inhibitor U0126 (5M) (C) for 2 h prior to PMA treatment (50
nM, 30 min). Cells were lysed, and protein expression and phosphorylation were analyzed by Western blot. Representative Western blots and their densito-
metric analyses are shown. Results aremeans S.E. (n 3–6 per treatment). All experiments were performed in triplicate. *, p 0.05 comparedwith control;
†, p 0.05 compared with PMA treatment.
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FIGURE 6. PMA stimulates PKD1 to impair insulin signaling. A and B, C2C12myotubes were treated with or without Go¨6983 (5M) or CRT0066101 (10M)
for 1h prior to PMA treatment (50 nM, 30 min), followed by insulin stimulation (100 nM, 15min). C and D, C2C12myotubes were transfected with scrambled or
PKD1 siRNA. 48 h later, theywere treatedwith PMA (50nM, 30min), followedby insulin stimulation (100nM, 15min). Cellswere lysed, andAkt, AMPK, PKD1, and
IRS-1phosphorylationwere analyzedbyWesternblot. Representativeblots (A,C) andquantifications (B,D) are shown. *,p0.05 comparedwith control; †,p
0.05 compared with insulin treatment.
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the cardiacmyocytes. In addition, our results indicate that ERK
was not involved in the phosphorylation of AMPK at Ser485/491
induced by PMA. These discrepancies could be due to differ-
ences in cell type or methodologies.
Several kinases have been reported to phosphorylate AMPK
at Ser485/491. We (4) and others (7) have shown that Akt phos-
phorylates and inhibits AMPK at this site in muscle, liver, and
heart in response to insulin. In the hypothalamus, the mTOR/
p70S6 kinase pathway has been reported to cause this inhibi-
tory event in response to leptin (5), an effect shown to be essen-
tial for mediating the anorectic effects of leptin. In murine
macrophage-like RAW 264.7 cells, Park et al. (12) showed that
IKK phosphorylates AMPK at Ser485 in response to LPS treat-
ment in mature dendritic cells. ERK1/2 was recently shown to
phosphorylate AMPK on this serine residue (13), an effect that
may be an important part of the mechanism by which CCR7
signaling promotes cell survival. Furthermore, protein kinase A
(PKA) has been reported to act as an upstream kinase for
AMPK Ser485/491 in INS-1 cells in response to forskolin or GIP
stimulation (14) and in humandiploid fibroblasts in response to
lysophosphatidic acid (15). We ruled out Akt, S6K, and ERK as
upstream kinases responsible for AMPK Ser485/491 phosphory-
lation in response to PMA treatment (Fig. 5); however, we have
identified PKD1 as a novel enzyme to be added to the growing
list of kinases which inhibit AMPK via Ser485/491 phosphoryla-
tion. Furthermore, we found a significant inverse correlation
between AMPK activity and phosphorylation at Ser485/491
under these conditions, suggesting that PKD1 is responsible for
the serine phosphorylation and inhibition of AMPK in this set-
ting (Fig. 3, B and D). The fact that expression of a phosphode-
fective S491A AMPK2 mutant prevented the PMA-induced
reduction in AMPK2 activity confirms that phosphorylation
of AMPK2 on Ser491 is required for PMA-induced inhibition
of AMPK kinase activity.
Many of the aforementioned kinases that canmediateAMPK
inhibition through Ser485/491 phosphorylation are associated
with anabolic or pro-hypertrophic signaling pathways (Akt,
mTOR/P70S6K). This is not surprising, since AMPK is gener-
ally activated under low energy conditions that favor catabolic
processes, and inhibited under conditions of energy overload
that favor anabolic processes. Consistent with this, PKD1 has
recently been identified as having pro-hypertrophic functions.
For example, Harrison et al. (21) reported that transgenic mice
expressing a cardiac-specific, constitutively active PKD1
mutant develop cardiac hypertrophy, followed by ventricular
chamber dilation, wall thinning, and contractile dysfunction.
They also showed that PKD1 expression and activity are signif-
icantly increased in the myocardium of spontaneously hyper-
tensive rats with heart failure, an effect that is further exagger-
ated by thoracic aortic banding. Furthermore, PKD1 activation
was found to be elevated in hearts of humans with idiopathic
dilated cardiomyopathy (20). While these results suggest that
FIGURE 7. Expression of S491AAMPK2 prevents the PMA-induced impairment in insulin signaling throughAkt. C2C12 cells were transfectedwithWT
AMPK2 or S491A AMPK2. 48 h later, cells were treatedwith PMA (50 nM, 30min) followed by insulin stimulation (100 nM, 15min). Cells were then lysed, and
Akt phosphorylation at Ser473 was analyzed by Western blot. A representative blot and quantification are shown. Results are means  S.E. (n  3–6 per
treatment). *, p 0.05 compared with WT insulin.
FIGURE8.RecombinantPKD1phosphorylatesAMPKatSer485/491 inacell-freeassay.RecombinantAMPK2/1/1was incubatedwith recombinantPKD1
or recombinant Akt as described under “Experimental Procedures.” Phosphorylation of AMPK at Ser491 was evaluated byWestern blot. Representative image
shown is from a single gel/exposure. A, consensus substrate motifs of PKD and Akt were lined up with residues 486–491 of AMPK2 (B). n 3 per group. All
experiments were performed in triplicate.
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PKD1 activation may be sufficient to induce pathological car-
diac remodeling, the role of PKD1 in skeletal muscle is less
clear. McGee et al. (25) reported that loss of AMPK in muscle
resulted in no change in HDAC5 phosphorylation during exer-
cise, but a33% compensatory increase in PKDactivation, sug-
gesting potential redundancies in the functions of these two
proteins in response to exercise. Although they did not investi-
gate the effects of PKD loss or activation on AMPK activation,
these data, together with our results, suggest that PKD and
AMPK may negatively regulate each other in skeletal muscle.
Further evidence supporting potential redundancy of func-
tions between AMPK and PKD1, at least in regards to HDAC5
phosphorylation in response to exercise, is the fact that mice
overexpressing constitutively active PKD1 in skeletal muscle
show resistance to fatigue in response to repetitive contraction
and a shift to Type I and Type IIa muscle fibers (26), while
expression of a dominant negative kinase dead PKD1 in skeletal
muscle results in impaired running performance and prevents
fiber type switching (27). Similarly, it has long been known that
AMPK mediates many adaptations of muscle to exercise (28),
and loss of AMPK in muscle causes impairments in running
capacity (29).
Our data showed that PKD1 activation impairs insulin-sig-
naling through Akt in C2C12 myotubes, an effect prevented
both by pharmacological inhibition and by genetic knockdown
of PKD1 (Fig. 6). PKC activation by PMA is known to impair
insulin signaling by causing serine phosphorylation of IRS-1.
Intriguingly, PKD1 knockdown did not reduce PMA-induced
serine phosphorylation of IRS-1, despite restoring insulin-stim-
ulatedAkt phosphorylation. These data suggest that PKD1 acti-
vation impairs insulin-signaling through an IRS-1-independent
mechanism, although the exact mechanism remains to be
determined. Additionally, we have shown that AMPK2 Ser491
is required for the observed impairment in insulin signaling,
though further studies are required to identify the exact mech-
anism (Fig. 7). Although AMPK2 is the predominant isoform
in skeletal muscle, the presence of AMPK1 Ser485 could
explainwhyAkt phosphorylation is not fully restored to control
levels. The present study is the first report of PKD1 activation
causing impaired insulin-signaling, and the mechanism by
which it does so requires further investigation, though we have
shown that it involves AMPK.
In summary, we have reported a novel inhibitory relationship
between PKD1 and AMPK in skeletal muscle cells whereby
PKD1 inhibits AMPK directly by phosphorylating it at Ser491 of
the 2 subunit. Since PKD1 may be activated directly by DAG
(or the DAGmimetic PMA) or by novel PKC isoforms, we have
not ruled out the possibility that novel PKC isoforms may also
be involved upstream of PKD1 in these processes. Similarly,
thoughwehave shown that PKD1 activation is necessary for the
inhibition of AMPK and that AMPK2 Ser491 is required for
the impairment of insulin signaling through Akt, further stud-
ies are required to further elucidate the pathway responsible for
this impairment. Our data suggest that PKD1 inhibitionmay be
a novel strategy for preventing AMPK inhibition and impaired
insulin sensitivity inmuscle; however, based on the growing list
of PKD1 functions in a variety of tissues being reported in the
literature, this strategy would have to be approached with cau-
tion, and likely in a highly controlled, tissue-specific manner.
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